tetano
Editor, Senior Moderator
Cell Biol Int
. 2023 Feb 5.
doi: 10.1002/cbin.11997. Online ahead of print.
COVID-19: A trigger of autoimmune diseases
Arghavan Zebardast[SUP] 1 [/SUP], Ali Hasanzadeh[SUP] 2 [/SUP], Seyedeh Arefeh Ebrahimian Shiadeh[SUP] 2 [/SUP], Mehdi Tourani[SUP] 3 [/SUP], Yousef Yahyapour[SUP] 4 [/SUP]
Affiliations
Abstract
The SARS-coronavirus-2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19), has spread worldwide and caused a global health emergency. SARS-CoV-2 is a coronaviridae virus that infects target cells by interacting with the plasma membrane-expressed angiotensin-converting enzyme 2 (ACE2) via the S1 component of the S protein. Effective host immune response to SARS-CoV-2 infection, which includes both innate and adaptive immunity, is critical for virus management and elimination. The intensity and outcome of COVID-19 may be related to an overabundance of pro-inflammatory cytokines, which results in a "cytokine storm" and acute respiratory distress syndrome. After SARS-CoV-2 infection, the immune system's hyperactivity and production of autoantibodies may result in autoimmune diseases such as autoimmune hemolytic anemia, autoimmune thrombocytopenia, Guillain-Barré syndrome, vasculitis, multiple sclerosis, pro-thrombotic state, and diffuse coagulopathy, as well as certain autoinflammatory conditions such as Kawasaki disease in children. We have reviewed the association between COVID-19 and autoimmune disorders in this article.
Keywords: COVID-19; SARS-CoV-2; autoantibody; autoimmune diseases; autoimmunity.
. 2023 Feb 5.
doi: 10.1002/cbin.11997. Online ahead of print.
COVID-19: A trigger of autoimmune diseases
Arghavan Zebardast[SUP] 1 [/SUP], Ali Hasanzadeh[SUP] 2 [/SUP], Seyedeh Arefeh Ebrahimian Shiadeh[SUP] 2 [/SUP], Mehdi Tourani[SUP] 3 [/SUP], Yousef Yahyapour[SUP] 4 [/SUP]
Affiliations
- PMID: 36740221
- DOI: 10.1002/cbin.11997
Abstract
The SARS-coronavirus-2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19), has spread worldwide and caused a global health emergency. SARS-CoV-2 is a coronaviridae virus that infects target cells by interacting with the plasma membrane-expressed angiotensin-converting enzyme 2 (ACE2) via the S1 component of the S protein. Effective host immune response to SARS-CoV-2 infection, which includes both innate and adaptive immunity, is critical for virus management and elimination. The intensity and outcome of COVID-19 may be related to an overabundance of pro-inflammatory cytokines, which results in a "cytokine storm" and acute respiratory distress syndrome. After SARS-CoV-2 infection, the immune system's hyperactivity and production of autoantibodies may result in autoimmune diseases such as autoimmune hemolytic anemia, autoimmune thrombocytopenia, Guillain-Barré syndrome, vasculitis, multiple sclerosis, pro-thrombotic state, and diffuse coagulopathy, as well as certain autoinflammatory conditions such as Kawasaki disease in children. We have reviewed the association between COVID-19 and autoimmune disorders in this article.
Keywords: COVID-19; SARS-CoV-2; autoantibody; autoimmune diseases; autoimmunity.